Gause J W, Day R J, Caraway C A, Poon W W, Rohn T T
University of Washington School of Medicine, Seattle, Washington, United States.
Department of Biological Sciences, Boise State University, Boise, Idaho, United States.
J Neurol Neurol Disord. 2017 Sep;3(2). doi: 10.15744/2454-4981.3.204. Epub 2017 Jul 31.
Recent studies have supported a role for the proteolytic cleavage of apolipoprotein as a potential mechanism for the enhanced dementia risk associated with Alzheimer's disease. To determine whether fragmentation is correlated with AD, ELISA assays were performed with cerebral spinal fluid (CSF) and plasma samples utilizing an antibody that specifically detects a 17 kDa amino-terminal fragment (p17) of (nApoECF antibody). In CSF samples, levels of fragmentation were minimal in both neuropathological normals (NPNs) and AD cases and there were no significant differences between the two cohorts across genotypes. Similar results were found in plasma samples where the p17 fragment comprised only 8.4% of the total level of identified APOE. As with CSF, there were no significant differences found between NPNs and AD cases in terms of the amount of nApoECF quantified. Taken together, these results suggest that the p17 amino-terminal fragment of is not correlated with AD or genotype in the plasma or CSF.
最近的研究支持载脂蛋白的蛋白水解切割作为与阿尔茨海默病相关的痴呆风险增加的潜在机制。为了确定载脂蛋白E片段化是否与阿尔茨海默病相关，使用一种特异性检测载脂蛋白E（nApoECF抗体）17 kDa氨基末端片段（p17）的抗体，对脑脊液（CSF）和血浆样本进行了酶联免疫吸附测定（ELISA）。在脑脊液样本中，神经病理学正常者（NPNs）和阿尔茨海默病患者的载脂蛋白E片段化水平均极低，并且在两种队列中不同载脂蛋白E基因型之间没有显著差异。在血浆样本中发现了类似的结果，其中p17载脂蛋白E片段仅占已鉴定载脂蛋白E总量的8.4%。与脑脊液一样，在定量的nApoECF量方面，NPNs和阿尔茨海默病患者之间没有发现显著差异。综上所述，这些结果表明，载脂蛋白E的p17氨基末端片段与血浆或脑脊液中的阿尔茨海默病或载脂蛋白E基因型无关。
